AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24954228
Drug: Oral vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vinorelbine 80 mg/m² on days 1 and 8 (first cycle 60 mg/m²) and cisplatin 80 mg/m² on day 1 (arm B)
Trial: 22642740
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose atenolol plus fixed dose losartan
Trial: 11488997
Drug: Cisplatin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (50 mg/m2, six cycles repeated every 28 days)
Trial: 10442510
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg once weekly
Trial: 10442510
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg once weekly
Trial: 7587033
Drug: Cefotaxime 1
RxNorm normalized name: cefotaxime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 1 g twice daily
Trial: 7587033
Drug: Cefotaxime 2
RxNorm normalized name: cefotaxime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 2 g twice daily
Trial: 20150021
Drug: Testosterone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (200 mg every 15 days)
Trial: 15569555
Drug: First questionnaire
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First questionnaire administered to first 50 randomly selected patients
Trial: 15569555
Drug: Second questionnaire
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second questionnaire administered to second group of randomly selected 50 patients
Trial: 11030484
Drug: Moclobemide (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (450 to 600 mg/day)
Trial: 1308526
Drug: Daily rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rifampicin for 9 months
Trial: 1308526
Drug: Standard WHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard WHO multidrug regimen (pulsed doses of rifampicin)
Trial: 6146390
Drug: Intramuscular midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular midazolam 0.07 mg/kg
Trial: 6146390
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam 0.2 mg/kg
Trial: 6146390
Drug: Intravenous thiopentone
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous thiopentone 3.0 mg/kg
Trial: 6146390
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 2.0 mg/kg
Trial: 22217432
Drug: High-frequency (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-frequency (15 Hz) rTMS treatment
Trial: 20298557
Drug: Group motivational
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group motivational intervention (32 group sessions, 1 to 12 fortnightly, and 13 to 32 monthly)
Trial: 8834097
Drug: d‐chlorpheniramine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐chlorpheniramine (4 mg)
Trial: 28446846
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise program (walking on treadmill, three times weekly until the end of 37 weeks of gestation) with diet control
Trial: 22281165
Drug: 0.5% INCB018424
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% INCB018424 phosphate cream
Trial: 22281165
Drug: 1.0% INCB018424
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% INCB018424 phosphate cream
Trial: 22281165
Drug: 1.5% INCB018424
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% INCB018424 phosphate cream (twice a day)
Trial: 22281165
Drug: Calcipotriene 0.005%
RxNorm normalized name: CALCIPOTRIENE 0.005% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriene 0.005% cream
Trial: 22281165
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate 0.05% cream
Trial: 20175820
Drug: Bromotetrandrine (BrTet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromotetrandrine (BrTet) 10 mg/m²
Trial: 20175820
Drug: Bromotetrandrine (BrTet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromotetrandrine (BrTet) 20 mg/m²
Trial: 20175820
Drug: Bromotetrandrine (BrTet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromotetrandrine (BrTet) 30 mg/m²
Trial: 11088064
Drug: Preoperative endocrine
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative endocrine therapy (3 to 4 months duration)
Trial: 8803300
Drug: Lisinopril with
RxNorm normalized name: LISINOPRIL 20 mg / HYDROCHLOROTHIAZIDE 25 mg ORAL TABLET [Lisinopril with Hydrochlorothiazide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril with or without diuretics
Trial: 8803300
Drug: Nifedipine with
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine with or without diuretics
Trial: 8803300
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (diuretics with or without vasodilators or selective beta-blockers)
Trial: 29807945
Drug: Iodine-containing contrast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine-containing contrast (0.3 mL)
Trial: 26655888
Drug: Kefir-fermented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kefir-fermented milk (1,600 mg) supplemented with calcium bicarbonate (CaCO3, 1,500 mg)
Trial: 26655888
Drug: Calcium bicarbonate
RxNorm normalized name: CALCIUM BICARBONATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium bicarbonate (CaCO3, 1,500 mg) alone (control)
Trial: 23605599
Drug: Low-power laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-power laser treatment
Trial: 22216772
Drug: Interactive voice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive voice recognition (IVR) intervention designed to prompt medication refills and improve ICS adherence
Trial: 18482632
Drug: Cold-pack therapy
RxNorm normalized name: Anbesol Cold Sore Therapy
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-pack therapy (vasoconstriction)
Trial: 17135646
Drug: Oral topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral topotecan (2.3 mg/m2/d, days 1 through 5, every 21 days) plus best supportive care (BSC)
Trial: 14735174
Drug: Oral topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral topotecan
Trial: 11132072
Drug: Propacetamol 20
RxNorm normalized name: Propanetriol
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol 20 mg/kg i.v.
Trial: 11132072
Drug: Piritramide 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piritramide 0.25 mg/kg i.m.
Trial: 11132072
Drug: Tramadol 1
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 1 mg/kg i.v.
Trial: 11132072
Drug: Diclofenac 1
RxNorm normalized name: diclofenac 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 1 mg/kg i.v.
Trial: 9252957
Drug: DHA oil
RxNorm normalized name: Ulkenia DHA oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA oil group (1.68 g/d DHA in triglyceride form)
Trial: 9252957
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil group (1.33 g EPA and 0.95 g DHA/d as free fatty acids)
Trial: 3526532
Drug: Amoxycillin (62
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (62 mg/kg/day)
Trial: 3526532
Drug: Pivampicillin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin (80 mg/kg/day)
Trial: 27253658
Drug: Suvorexant (40,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant (40, 80, and 150 mg)
Trial: 24385309
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR 300 mg
Trial: 24385309
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR 800 mg
Trial: 24385309
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (all doses)
Trial: 21052041
Drug: venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: venlafaxine ER (75 to 225 mg/d)
Trial: 16632013
Drug: Valsartan, 80
RxNorm normalized name: Valsartan, 80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan, 80 mg/d (titrated up to 160 mg/d for blood pressure control)
Trial: 10963823
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (0.025 U/kg BW)
Trial: 10963823
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (0.05 U/kg BW)
Trial: 10963823
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (0.025 U/kg BW)
Trial: 10963823
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (0.05 U/kg BW)
Trial: 10963823
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (any dose)
Trial: 8139394
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (30 g/d)
Trial: 29368598
Drug: Standard treatment/control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment/control (CN)
Trial: 27310241
Drug: Baseline psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline psychological treatment
Trial: 27310241
Drug: Baseline antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline antidepressant medications
Trial: 23733443
Drug: HiDHA (tuna
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HiDHA (tuna oil) supplementation (8 × 1 g capsules per day for 16 weeks)
Trial: 23733443
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (placebo) supplementation (8 × 1 g capsules per day for 16 weeks)
Trial: 21414950
Drug: Symptom-triggered self-medication
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-triggered self-medication with chlordiazepoxide
Trial: 19108693
Drug: Ad5 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5 vaccine
Trial: 19108693
Drug: MRKAd5 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRKAd5 vaccine
Trial: 15364161
Drug: Morning dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dose of insulin glargine
Trial: 15364161
Drug: Evening dose
RxNorm normalized name: Jornay PM, (evening dose) 60 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dose of insulin glargine
Trial: 15364161
Drug: Split dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split dose of insulin glargine
Trial: 9894621
Drug: Captopril (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (37.5 mg/day)
Trial: 8672317
Drug: Digital pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital pressure applied on the neurovascular sheath during injection of 2% mepivacaine with adrenaline (20 ml) mixed with contrast agent (20 ml).
Trial: 8672317
Drug: Digital pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital pressure applied 6-8 cm below the neurovascular sheath during injection of 2% mepivacaine with adrenaline (20 ml) mixed with contrast agent (20 ml).
Trial: 2088996
Drug: 30‐mg controlled‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30‐mg controlled‐release morphine tablet (MS Contin Tablet) after a high fat meal
Trial: 2088996
Drug: 30‐mg controlled‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30‐mg controlled‐release morphine tablet (MS Contin Tablet) after fasting
Trial: 28738490
Drug: Ultrafiltration therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrafiltration therapy for 8 hours
Trial: 1932608
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet of enalapril (10 mg) and hydrochlorothiazide (25 mg)
Trial: 1932608
Drug: Enalapril tablet
RxNorm normalized name: enalapril Oral Tablet
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril tablet (10 mg)
Trial: 1932608
Drug: Hydrochlorothiazide tablet
RxNorm normalized name: Hydrochlorothiazide Tablets
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide tablet (25 mg)
Trial: 1932608
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of separate tablets of enalapril (10 mg) and hydrochlorothiazide (25 mg)
Trial: 7015537
Drug: Oxprenolol HCl
RxNorm normalized name: oxprenolol HCl
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxprenolol HCl 160 mg slow-release plus cyclopenthiazide 0.25 mg and potassium chloride 600 mg
Trial: 30025819
Drug: HER2-peptide vaccines
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HER2-peptide vaccines
Trial: 27514617
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg prasugrel
Trial: 16144987
Drug: Valsartan (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (160 mg/d) administered on awakening
Trial: 7489584
Drug: Aktiferrin capsules
RxNorm normalized name: Yttrium (90Y) Antiferritin Polyclonal Antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aktiferrin capsules
Trial: 6896406
Drug: Allopurinol (xanthine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (xanthine oxidase inhibitor)
Trial: 29145788
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) delivered via videoconferencing
Trial: 29145788
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) delivered in-person
Trial: 29555631
Drug: Rezafungin (CD101)
RxNorm normalized name: Rezafungin
DrugBank: Rezafungin (DB16310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rezafungin (CD101) administered intravenously
Trial: 24159790
Drug: Cycloferon (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycloferon (7.5 g) combined with antibacterial therapy
Trial: 20735821
Drug: Triple anti-platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple anti-platelet therapy (cilostazol, aspirin, clopidogrel)
Trial: 20735821
Drug: Dual anti-platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual anti-platelet therapy (aspirin and clopidogrel)
Trial: 20735821
Drug: Triple anti-platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple anti-platelet therapy
Trial: 20735821
Drug: Dual anti-platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual anti-platelet therapy
Trial: 18426639
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg folic acid daily
Trial: 10481354
Drug: Tele-medicine system
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele-medicine system for asthma management
Trial: 27717222
Drug: Exenatide once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide once-weekly (subcutaneous injections)
Trial: 22028071
Drug: 20 µg of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg of HyD per day
Trial: 22028071
Drug: 20 µg (800 IU)
RxNorm normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 µg (800 IU) of vitamin D(3) per day
Trial: 9711797
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms of recombinant hepatitis B vaccine (GenHevac B) intramuscularly (i.m.)
Trial: 9711797
Drug: 2 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 micrograms of recombinant hepatitis B vaccine (GenHevac B) intradermally (ID)
Trial: 7974084
Drug: Cobalt-60 therapy
RxNorm normalized name: Cobalt
DrugBank: Cobalt (DB14574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobalt-60 therapy followed by hormonotherapy after progression
Trial: 31912784
Drug: Graded Exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded Exercise Therapy (GET) for 12 weeks
Trial: 23957590
Drug: Probiotic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic mixture (Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5, Bifidobacterium Bb12) 1.3 × 10(10) CFU per capsule, two capsules twice daily for 6 months
Trial: 23957590
Drug: Placebo, two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, two capsules twice daily for 6 months
Trial: 21834970
Drug: Enhanced pharmacist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced pharmacist care (patient identification, assessment, education, close follow‐up, and prescribing/titration of antihypertensive medications)
Trial: 22500389
Drug: Modified Shenqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Shenqi Dihuang Decoction (MSDD) plus basic treatment of Western medicine
Trial: 22500389
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment of Western medicine alone
Trial: 17290328
Drug: Targeted therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapies (tyrosine kinase and angiogenesis inhibitors)
Trial: 9172168
Drug: Increased risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased risk for NIDDM (defined by higher 2 h glucose and insulin values on oral glucose tolerance testing)
Trial: 8385741
Drug: Sulindac (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (150 mg orally twice a day for nine months)
Trial: 3957482
Drug: Oral terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbutaline (5 mg three times daily for two weeks)
Trial: 22364383
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention with drug-eluting stent (DES-PCI)
Trial: 15882173
Drug: Preoperative combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative combined chemoradiation (external‐beam radiotherapy to 45 Gy plus weekly cisplatin 50 mg/m2)
Trial: 15882173
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAIC) (cisplatin 50 mg/m2 and vincristin 1 mg/m2 every 7‐10 days for three courses)
Trial: 14624765
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment (Genotropin, Pharmacia Corporation) for 6 months
Trial: 6283422
Drug: Amitriptyline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (75 mg median dose)
Trial: 27652610
Drug: Standard prasugrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prasugrel therapy (control group)
Trial: 27652610
Drug: De-escalating therapy
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De-escalating therapy (one-week prasugrel followed by one-week clopidogrel and PFT-guided maintenance therapy)
Trial: 29127842
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (0.5mg/day)
Trial: 12357162
Drug: Intrathecal adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal adenosine 0.5 mg
Trial: 12357162
Drug: Intrathecal adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal adenosine 2.0 mg
Trial: 14557958
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine (PncOMPC)